JESSICA SWANSON: Open Payments
NPI 1467144741 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,345 in 200 payments from 17 companies in 2025. Trend: 2023 $963 · 2024 $2,303 · 2025 $4,345
Food & beverage: $4,233Education: $111
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 23 | $753 |
| Teva Pharmaceuticals USA, Inc. | 29 | $629 |
| Alkermes, Inc. | 22 | $547 |
| Otsuka America Pharmaceutical, Inc. | 22 | $469 |
| E.R. Squibb & Sons, L.L.C. | 22 | $465 |
| ABBVIE INC. | 25 | $324 |
| Vanda Pharmaceuticals Inc. | 11 | $317 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $210 |
| Janssen Pharmaceuticals, Inc | 7 | $143 |
| Axsome Therapeutics, Inc. | 7 | $132 |
Products named: INGREZZA, COBENFY, ARISTADA, REXULTI, VRAYLAR, FANAPT, AUSTEDO XR, UZEDY.
Industry payments across FL — which companies pay providers there.
